The recent CAPRIE trial (clopidogrel versus aspirin in patients at risk of ischaemic events) compared clopidogrel with aspirin in reducing the risk of vascular events in 19 185 patients with clinical manifestations of atherosclerosis. Participants were randomized to receive daily oral clopidogrel (75 mg) or aspirin (325 mg). Treatment periods ranged from 1 to 3 years. The primary outcome measurement was an aggregate of myocardial infarction, ischemic stroke and vascular death. Event rates of 5.32% and 5.83% were associated with clopidogrel and aspirin therapy, respectively. Clopidogrel therapy resulted in a relative risk reduction of 8.7% (CI 0.3-16.5%) compared with aspirin therapy (p = 0.043). Gastrointestinal hemorrhages occurred in 1.99% of patients treated with clopidogrel and 2.66% of patients treated with aspirin (p Ͻ 0.002). There were no significant treatment-based differences in the rates of intracerebral hemorrhages and hemorrhagic deaths or thrombocytopenia. These results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis.
Introduction
The Antiplatelet Trialists' Collaboration, 1 a meta-analysis of 145 clinical trials involving antiplatelet prophylaxis in over 70 000 patients at high risk for vascular events, found an approximate 25% overall risk reduction with the use of antiplatelet therapy, consisting primarily of aspirin. Among all high-risk patients, non-fatal myocardial infarction (MI) and non-fatal strokes were reduced by about one-third, while vascular deaths were reduced by about one-sixth. Although trials using a variety of aspirin doses were included in the meta-analysis, there was no evidence that higher doses conferred a greater protective effect. The duration of 21 of the trials, comprising approximately 56 000 patients, was at least 1 year. After 1, 2 and 3 years of follow-up, there was a reduction in the risk of an adverse cardiovascular event of 28%, 24% and 12% respectively, in patients treated with antiplatelet therapy compared with controls. 1 Although the Collaboration's meta-analysis did not examine safety data for aspirin therapy, long-term therapy is associated with a variety of side-effects. The most common adverse effects include bleeding, gastrointestinal discomfort, ulcer and, in certain hypersensitive patients, bronchoconstriction. [2] [3] [4] [5] [6] Clopidogrel is a thienopyridine derivative that inhibits platelet aggregates by antagonizing the platelet adenosine diphosphate receptor. A recent, large, multicenter trial, CAPRIE (clopidogrel versus aspirin in patients at risk of ischaemic events), compared the effects of clopidogrel with those of aspirin in patients thought to be at high risk for vascular events.
CAPRIE
The results of the CAPRIE study have been published previously. 7 In this article, I wish to review and summarize those results. The two major objectives of the CAPRIE trial were 1 to assess the relative efficacy of clopidogrel and aspirin in reducing the incidence of ischemic stroke, myocardial infarction, or vascular death among patients who had survived a recent ischemic stroke, recent myocardial infarction, or had symptomatic atherosclerotic peripheral arterial disease; and (2) to assess the relative safety and tolerability of clopidogrel and aspirin. CAPRIE enrolled over 19 000 patients with clinical disorders indicative of atherothrombotic vascular disease, including stroke, myocardial infarction, and peripheral arterial disease. The primary endpoint of the study was a composite outcome cluster of myocardial infarction, ischemic stroke, or vascular death.
Inclusion criteria for patients with ischemic stroke were a focal neurologic deficit likely to be of atherothrombotic origin with an onset greater than 1 week, but less than 6 months, before enrollment; neurologic signs persisting for longer than 1 week from onset; and computed tomography or magnetic resonance imaging evidence that the cause of stroke was not hemorrhagic or of non-vascular origin. Patients with myocardial infarction were eligible if its onset was 35 or fewer days before enrollment, as indicated by the presence of any two of the following criteria: ischemic pain lasting у20 min; creatine kinase, creatine kinase-MB, lactic dehydrogenase, or aspartate transaminase levels elev-ated to twice the laboratory normal without explanation; the development of new у40 msec Q waves in at least two adjacent ECG leads or a new dominant R wave in V1 (R у 1 mm Ͼ S in V1). Patients enrolled because of peripheral arterial disease were required to have a history of intermittent claudication as indicated by the World Health Organization criterion -leg pain while walking that disappears after less than 10 min of standing still. The pain must have been of presumed atherosclerotic origin. Further, the patients were required to have an ankle-arm systolic blood pressure ratio р0.85 in either leg at rest on two separate occasions. In addition, patients with a history of intermittent claudication who had undergone reconstructive surgery, angioplasty, or leg amputation with no persisting complications from the intervention, were eligible for enrollment. Thus, patients who enrolled with peripheral arterial disease were distinguished from the other two groups, in part, by the chronicity of symptoms.
Patients were randomly assigned to receive either aspirin (325 mg/day) or clopidogrel (75 mg/day). The protocol allowed the use of standard therapies appropriate to the patient's symptoms during the study; however, anticoagulant or antithrombotic medications were discontinued before randomization.
Patient follow-up
The 19 185 patients enrolled in CAPRIE were followed for up to 3 years, with a mean follow-up period of 1.91 years. The thienopyridine derivative, ticlopidine, is associated with an increased risk of neutropenia and thrombocytopenia. Thus, during the first 3 months of the study, weekly blood counts and bimonthly biochemical assessments were obtained from the first 500 patients in an intensive safety examination. Review of those data alleviated concern about clopidogrel's safety, and the intense scrutiny was relaxed to monthly follow-up for the first 4 months and once every 4 months for the remainder of the study.
The primary outcome event cluster consisted of the first occurrence of ischemic stroke, myocardial infarction, or death from vascular causes (vascular death). Secondary outcome clusters consisted of the above outcome events plus amputation; vascular death; any stroke, myocardial infarction, or death from any cause; and death from any cause.
The clinical subgroups defined by the three sets of inclusion criteria comprised approximately equal numbers of patients: 6431 patients were enrolled because of stroke, 6302 because of myocardial infarction and 6452 because of peripheral arterial disease. The two treatment groups were well matched in terms of age, sex, race and risk factors. Risk factors for atherosclerosis, including diabetes mellitus, high blood pressure, hypercholesterolemia and current cigarette smoking, were roughly comparable between the two groups.
Only 42 patients (0.22%) were lost to follow-up; they were evenly balanced between treatment groups. Treatment was discontinued early during the study in approximately 21% of patients in each group for a variety of reasons, including adverse side-effects, withdrawn consent, and non-compliance.
Efficacy
An intention-to-treat analysis found that during 17 636 patient years at risk, 939 events occurred in the clopidogrel Vascular Medicine 1998; 3: 257-260 group at an average rate of 5.32% per year. In the 17 519 patient years at risk among aspirin-treated patients, 1021 events occurred at an average of 5.83% per year. Therefore, the absolute risk reduction achieved with clopidogrel compared with aspirin was 0.51% per year. Using a Cox proportional-hazard model, the relative risk reduction achieved by clopidogrel compared with aspirin was 8.7% (95% CI 0.3-16.5; p = 0.043). An on-treatment analysis of the data (including patients receiving only the study drug or data taken from patients within 28 days of discontinuation of the study drug) revealed a relative risk reduction of 9.4% in favor of clopidogrel. The cumulative risk of experiencing an outcome event within the primary outcome cluster during the study is shown in Figure 1 . Analysis of the data for the secondary outcomes provided similar relative risk reductions of 7-8% in favor of clopidogrel for the cluster of ischemic stroke, myocardial infarction, amputation, or vascular death (p = 0.076), for vascular death (p = 0.29); and for any stroke, myocardial infarction, or death from any cause (p = 0.81) The relative risk reduction for death from any cause was 2.2% (p = 0.71).
As would be expected, strokes were the most common outcome event among those admitted because of stroke, and myocardial infarctions were most common among those admitted because of myocardial infarction. Among patients enrolled because of peripheral arterial disease, outcome events were evenly divided among myocardial infarction, stroke and other vascular deaths.
Although analyses based on the clinical subgroups were performed with CAPRIE data, the study was not originally powered to perform such calculations and caution should be used in their interpretation. By clinical subgroup, the relative risk reduction achieved by clopidogrel therapy for myocardial infarction, stroke and peripheral arterial disease patients were −3.7%, 7.3% and 23.8%, respectively. Because of these findings, concern has been raised regarding the acute myocardial infarction subgroup. To assess the effect of clopidogrel therapy further in patients with prior myocardial infarction, an additional analysis was performed that included 2144 patients in the stroke and peripheral arterial disease groups who had, in addition, a history of myocardial infarction. In this group, clopidogrel was associated with a 22.7% relative risk reduction over aspirin in preventing vascular events. 7 When this group was combined with the acute myocardial infarction subgroup, there were 455 events in clopidogrel-treated patients and 479 events in aspirin-treated patients; this is a relative risk reduction of 7.4%, which is consistent with the overall findings of the study. 7 A subsequent analysis of all 19 185 patients in CAPRIE 8 examined the relative risk reductions for the individual outcome events of myocardial infarction (fatal and non-fatal). In the clopidogrel group there were 276 events, whereas in the aspirin group there were 341 events. This is equivalent to a relative risk reduction by clopidogrel of 19.2% for fatal and non-fatal myocardial infarction (p Ͻ 0.008).
The relative risk reductions achieved with clopidogrel in this study are probably in addition to the benefit already afforded by aspirin therapy, since the latter has been compared to placebo in the Antiplatelet Trialists' Collaboration, which suggested that aspirin reduces the risk of vascular events by about 25% compared with placebo. This 25% reduction is equivalent to the prevention of 19 serious vas- The absolute efficacy of clopidogrel compared with placebo cannot be determined from the CAPRIE study since there was no placebo arm, and it would have been unethical to omit antiplatelet therapy from the management of patients with symptomatic atherosclerosis.
Safety
The assessment of clopidogrel's safety was an important objective of the CAPRIE study. Clopidogrel has a favorable safety profile compared to that of aspirin. Hemorrhagic events are a concern in patients receiving antiplatelet therapy. Intracranial hemorrhages and hemorrhagic deaths occurred in 0.39% of the clopidogrel patients and 0.53% of patients receiving aspirin (p = NS). However, gastrointestinal hemorrhages occurred in 1.99% of patients treated with clopidogrel and 2.66% of those treated with aspirin (p Ͻ 0.05). There were 30% more hospitalizations for gastrointestinal bleeding in the aspirin-treated group than in the clopidogrel-treated group. In terms of gastrointestinal disorders, including indigestion, nausea, or vomiting, 15.01% of clopidogrel-treated patients experienced events versus 17.59% of the aspirin group (p Ͻ 0.05). It is important to note that patients with a history of aspirin intolerance were excluded from the CAPRIE trial. Thus, rates of adverse gastrointestinal events reported with aspirin in this study may differ from that which occurs in the general population.
Neutropenia is an adverse effect of ticlopidine, an analogue of clopidogrel, occurring in about 1% of treated patients. In CAPRIE, the rate of neutropenia was similar in the aspirin and clopidogrel groups. Neutropenia occurred in about 0.1% of patients treated with clopidogrel and 0.17% of those receiving aspirin (p = NS). Severe neutropenia occurred in 0.05% (five patients) of those treated with clopidogrel versus 0.04% (four patients) of those treated with aspirin (p = NS). Vascular Medicine 1998; 3: 257-260
The incidence of diarrhea was significantly greater with clopidogrel (4.5%) than with aspirin (3.4%; p Ͻ 0.05), although it occurred infrequently with either drug. Rashes also occurred significantly more frequently in the clopidogrel group (6% versus 5% with aspirin; p Ͻ 0.05); severe rashes occurred in only 0.26% of patients treated with clopidogrel and 0.10% of patients receiving aspirin.
Conclusions
To summarize the findings of CAPRIE, long-term administration of clopidogrel to patients primarily with atherosclerosis as a cause of vascular disease is more effective than long-term aspirin therapy in reducing the combined risk of ischemic stroke, myocardial infarction, or vascular death. The relative risk reduction provided by clopidogrel, as seen in the CAPRIE trial, is added to the benefit provided by aspirin when compared with placebo. Clopidogrel is an effective antiplatelet agent that reduces cardiovascular events and it does so with a favorable safety profile.
